A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis.
CONCLUSION: Both Genz-644470 and sevelamer carbonate effectively lowered serum phosphate levels in a dose-dependent fashion in patients with chronic kidney disease on hemodialysis. However, Genz-644470 did not provide any advantage over sevelamer carbonate in phosphate lowering in vivo, as had been demonstrated in vitro.
PMID: 24748812 [PubMed] (Source: International Journal of Nephrology and Renovascular Disease)
Source: International Journal of Nephrology and Renovascular Disease - November 28, 2015 Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research
Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not on Dialysis in Bulgaria
Conclusions The equal efficacy, similar adverse effect profile, and lower cost of SC when used for the treatment of hyperphosphatemia in patients with CKD not on dialysis should make it a preferred alternative. (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - November 13, 2015 Category: Global & Universal Source Type: research
Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD
In conclusion, treatment with FC as a phosphate binder results in increased iron parameters apparent after 12 weeks and reduces iv iron and ESA use while maintaining hemoglobin over 52 weeks, with a safety profile similar to that of available binders. (Source: Journal of the American Society of Nephrology : JASN)
Source: Journal of the American Society of Nephrology : JASN - September 30, 2015 Category: Urology & Nephrology Authors: Umanath, K., Jalal, D. I., Greco, B. A., Umeukeje, E. M., Reisin, E., Manley, J., Zeig, S., Negoi, D. G., Hiremath, A. N., Blumenthal, S. S., Sika, M., Niecestro, R., Koury, M. J., Ma, K.-N., Greene, T., Lewis, J. B., Dwyer, J. P., for the Collaborative S Tags: Clinical Research Source Type: research
Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland
Conclusions
The use of PA21 versus SC in hyperphosphataemic patients being intolerant of calcium-based phosphate binders may be cost saving and yields only very limited disadvantages in terms of quality-adjusted survival. PA21 appears to be cost-effective from the perspective of the Scottish NHS. (Source: PharmacoEconomics)
Source: PharmacoEconomics - September 3, 2015 Category: Health Management Source Type: research
Renal formulas pretreated with medications alters the nutrient profile
Conclusions
Pretreating formula with medications alters nutrients other than the intended target(s). Future studies should be aimed at predicting the loss of these nutrients or identifying alternative methods for managing serum potassium and phosphorus levels in formula-fed infants. The safety of pretreating formula with SPS suspension should also be examined. (Source: Pediatric Nephrology)
Source: Pediatric Nephrology - August 26, 2015 Category: Urology & Nephrology Source Type: research
Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data
Conclusions
Phosphate binding with FC reduces IV iron and ESA usage. Given the high cost burden of ESRD, our model demonstrates significant potential cost savings.
Trial Registration
ClinicalTrials.gov (NCT01191255) http://clinicaltrials.gov/ct2/show/NCT01191255. (Source: Drugs in R&D)
Source: Drugs in R&D - August 3, 2015 Category: Drugs & Pharmacology Source Type: research
Novel iron-based phosphate binders in patients with chronic kidney disease
Purpose of review: Management of hyperphosphatemia remains an integral component in the care of patients with chronic kidney disease on dialysis. In addition to dietary restriction and dialysis, oral phosphate binders remain a key strategy in the control of serum phosphorus levels in this population. We review two new oral phosphate binders that are currently marketed in the United States.
Recent findings: Sucroferric oxyhydroxide was approved by the U.S. Food and Drug Administration (FDA) in November 2013. A recent international, multicenter study found the drug to be efficacious and noninferior to sevelamer carbonate in ...
Source: Current Opinion in Nephrology and Hypertension - June 12, 2015 Category: Urology & Nephrology Tags: MINERAL METABOLISM: Edited by Myles Wolf and David A. Bushinsky Source Type: research
Sp643 * sevelamer carbonate vs. lanthanum carbonate vs. calcium acetate/magnesium carbonate in ckd patients on hemodialysis: a randomized study
(Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Ekart, R., Bevc, S., Dvorsak, B., Hojs, N., Hren, M., Jakopin, E., Knehtl, M., Stropnik Galuf, T., Hojs, R. Tags: DIALYSIS. BONE DISEASE Source Type: research
Fp409 * sevelamer carbonate reduces phosphaturia but has no effect on serum c-terminal fibroblast growth factor 23 levels in stage 3b/4 ckd patients : the results of a french, multicenter, double-blind, placebo-control, randomized clinical trial
(Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Liabeuf, S., Ryckelink, J. p., El Esper, N., Urena, P., Combe, C., Dussol, B., Fouque, D., Vanhille, P., Frimat, L., Thervet, E., Prie, D., Choukroun, G. Tags: CHRONIC KIDNEY DISEASE. BONE DISEASE Source Type: research
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
Conclusions
The serum phosphorus-lowering effect of sucroferric oxyhydroxide was maintained over 1 year and associated with a lower pill burden, compared with sevelamer. Sucroferric oxyhydroxide was generally well tolerated long-term and there was no evidence of iron accumulation. (Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - May 20, 2015 Category: Urology & Nephrology Authors: Floege, J., Covic, A. C., Ketteler, M., Mann, J. F. E., Rastogi, A., Spinowitz, B., Chong, E. M. F., Gaillard, S., Lisk, L. J., Sprague, S. M., on behalf of the Sucroferric Oxyhydroxide Study Group Tags: Intra- and extracorporeal treatments of kidney failure Source Type: research
The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial
Conclusions Ferric citrate was associated with similar phosphorus control compared to active control, with similar effects on markers of bone and mineral metabolism in dialysis patients. There was no evidence of protein-energy wasting/inflammation or aluminum toxicity, and fewer participants randomly assigned to ferric citrate had serious adverse events. Ferric citrate is an effective phosphate binder with a safety profile comparable to sevelamer and calcium acetate. (Source: American Journal of Kidney Diseases)
Source: American Journal of Kidney Diseases - May 9, 2015 Category: Urology & Nephrology Source Type: research
Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment
Abstract
Hyperphosphatemia is common in patients with chronic renal failure. Phosphate binders are associated with gastric intolerance, representing the main reason of drug discontinuation. The aim of this study was to compare the effects in vitro and in vivo of sevelamer hydrochloride (SH), sevelamer carbonate (SC) and lanthanum carbonate (LC) on gastric microenvironment. We have also evaluated the efficacy and tolerability of these drugs in hemodialysis (HD) patients. In vitro analysis: Dissolution time, ability to uptake phosphorus, changes in pH starting from gastric milieu and the amount of carbon dioxide (CO2) produc...
Source: Therapeutic Apheresis and Dialysis - April 1, 2015 Category: Hematology Authors: Giuseppe Coppolino, Silvia Lucisano, Laura Rivoli, Giorgio Fuiano, Antonino Villari, Iole Villari, Grazia Leonello, Antonio Lacquaniti, Domenico Santoro, Michele Buemi Tags: Original Article Source Type: research
Sucroferric Oxyhydroxide: A Review in Hyperphosphataemia in Chronic Kidney Disease Patients Undergoing Dialysis
In conclusion, sucroferric oxyhydroxide is a valuable treatment option for hyperphosphataemia in CKD patients on dialysis, providing an effective and generally well tolerated noncalcium-based phosphate binder therapy with a lower pill burden than sevelamer carbonate and the potential for improved treatment adherence. (Source: Drugs)
Source: Drugs - March 12, 2015 Category: Drugs & Pharmacology Source Type: research
Effects of Sevelamer Carbonate on Advanced Glycation End Products and Antioxidant/Pro-Oxidant Status in Patients with Diabetic Kidney Disease.
CONCLUSIONS: SC reduced circulating and cellular AGEs, increased antioxidants, and decreased pro-oxidants, but did not change HbA1c or the albumin/creatinine ratio overall in patients with T2DM and DKD. Because subanalyses revealed that SC may reduce HbA1c and albuminuria in some patients with T2DM with DKD, further studies may be warranted.
PMID: 25710801 [PubMed - as supplied by publisher] (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - February 20, 2015 Category: Urology & Nephrology Authors: Yubero-Serrano EM, Woodward M, Poretsky L, Vlassara H, Striker GE, on behalf of AGE-less Study Group Tags: Clin J Am Soc Nephrol Source Type: research
Cost- minimization analysis of the direct costs of sevelamer carbonate and lanthanum carbonate in the treatment of ckd-nd patients
The objective of this study is to perform cost - minimization analysis of the newly available medicines sevelamer carbonate (SC) and lanthanum carbonate (LC), for the treatment of hyperphosphatemia in CKD patients not on dialysis (CKD-ND) in Bulgaria. (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: M.K. Petrov, M. Dimitrova, G.I. Petrova Source Type: research
